Fundraising FoxISOThrive
Healdsburg, US · Delaware corporation · 2 known investors
Find your way into ISOThrive
Sign up to find every way you can get introduced to ISOThrive
- Your email: who you already know at ISOThrive, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the ISOThrive team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
ISOThrive is a clinical-stage biotech company developing proprietary digestion-resistant carbohydrates that target specific bacteria to correct microbiome dysbiosis, aimed at treating chronic diseases linked to microbiome imbalance. Its lead asset, ISOT-101 (maltosyl-isomaltooligosaccharide/MIMO), is in a phase 2 study.
Founders & leadership
JO
Jack OswaldNamed on SEC filing
AO
Alyn OswaldNamed on SEC filing
Board
JJ
James J. FarrellBoard director
MW
MIKE WALTHERBoard director
FK
FADI KARAMBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$17.4M disclosed across 3 rounds · 2019–2025
▶$8.1MraisedNov 2025 · 12 investors · Other Health CareRule 506(b)
▶$8.1MraisedNov 2025 · 12 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- JAMES J. FARRELLDirector
- MIKE WALTHERDirector
- JACK OSWALDExecutive Officer, Director
- ALYN OSWALDExecutive Officer, Director
- FADI KARAMDirector
- Offering amount
- $9.8M
- Amount sold
- $8.1M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.2MraisedFeb 2021 · 11 investors · Other Health CareRule 506(b)
▶$5.2MraisedFeb 2021 · 11 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Fadi KaramDirector
- James J. FarrellDirector
- Alyn OswaldDirector
- Mike WaltherDirector
- Jack OswaldExecutive Officer, Director
- Offering amount
- $6M
- Amount sold
- $5.2M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedNov 2019 · 25 investors · Other Health CareRule 506(b)
▶$4MraisedNov 2019 · 25 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jack OswaldExecutive Officer, Director
- James J. FarrellDirector
- Alyn OswaldDirector
- Offering amount
- $12M
- Amount sold
- $4M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does ISOThrive do?
- ISOThrive is a clinical-stage biotech company developing proprietary digestion-resistant carbohydrates that target specific bacteria to correct microbiome dysbiosis, aimed at treating chronic diseases linked to microbiome imbalance. Its lead asset, ISOT-101 (maltosyl-isomaltooligosaccharide/MIMO), is in a phase 2 study.
- Who are ISOThrive's investors?
- ISOThrive's investors include Alumni Ventures, Neer Venture Partners.
- How much funding has ISOThrive raised?
- ISOThrive has disclosed $17.4M raised across 3 rounds.
- Where is ISOThrive headquartered?
- ISOThrive is headquartered in Healdsburg, US.